Representative Issuers
Charlie has represented companies/investment banks on capital market transactions involving issuers across industries, such as: AbCellera, Accelerate, Acutus, Advaxis, Aerohive, Agenus, Akari, Akcea, Akero, Allogene, Alteryx, Ambrx, Amylin, Anadys, AnaptysBio, Angion, Annexon, Anthera, Apigee, Applied Molecular Transport, Arcadia, Arcus, Arcutis, Ardea, Arena, Aridis, Ascendis, ASLAN, Athira, Audentes, Avidity, Ballast Point Brewing & Spirits, Biomea, Cadence, Castlight, Cerus, Cidara, Clorox, Corcept, Crinetics, Cue Health, Cyan, Cytori, Day One, Dermira, Design, DICE, Doximity, Dynavax, eBay, EHang, Eidos, Elevation Oncology, Entropic, Erasca, Exagen, Evofem, Fangdd, FIGS, FireEye, Five Prime, Gemphire, Genomatica, Global Blood Therapeutics, Gossamer, Gracell, Graphite Bio, Gritstone, Guardant Health, Halozyme, Health Catalyst, Healthcare Royalty, HealthEquity, Horizon, IGM, Ignyta, Immune Design, IMV, Inhibrx, Inovio, Insys, Invitae, Ionis, Janux, Jazz Pharmaceuticals, Kamada, Kinnate, Kite Pharma, Kronos, Landry's, LifeLock, Limelight, Livongo, Longboard, Lyell, MannKind, Medallia, MethylGene, Metropark, MindBody, Minerva, Mirati, NantHealth, NantKwest, Nektar, Neon, Neurocrine, ObsEva, Olink, Ooma, Optimer, ORIC, Otonomy, Pernix, Phathom, Poseida, PRA Holdings, PROCEPT, Progressive Gaming, ProNAi, ProQR, Proto Labs, Qualtrics, Quidel, Radiant Systems, Rani, Raptor, Reata, Receptos, Regulus, ReSearch Pharmaceutical Services, Sana, Sangamo, Santarus, Seattle Genetics, Senomyx, Sequenom, ShockWave, Sierra, Silverback, Singular Genomics, Somaxon, Strongbridge, Surface Oncology, Sutro, Syndax, Tableau Software, Tabula Rasa, Taiwan Liposome Company, Tangoe, TRACON, Treace, Tricida, Trius, TriVascular Technologies, Uber Technologies, Vaxcyte, Ventyx Biosciences,, Verenium, Verona, Vical, ViewRay, Vir, Vital Therapies, Vor, Xencor, Xenon, XenoPort, Zealand Pharma, Zentalis, Zogenix, Zscaler, Zymeworks, 4D Molecular Therapeutics,10x Genomics and 89bio.